Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration
Open accessThe DOI matches its Crossref record; 181 of the 181 references it cites were found in a registry or an index; 51 of the 251 sources its claims cite were checked for support.
Abstract
The diagnosis of neurodegenerative disorders is often challenging due to the lack of diagnostic tools, comorbidities and shared pathological manifestations. Synaptic dysfunction is an early pathological event in many neurodegenerative disorders, but the underpinning mechanisms are still poorly characterised. Reliable quantification of synaptic damage is crucial to understand the pathophysiology of neurodegeneration, to track disease status and to obtain prognostic information. Neuronal pentraxins (NPTXs) are extracellular scaffolding proteins emerging as potential biomarkers of synaptic dysfunction in neurodegeneration. They are a family of proteins involved in homeostatic synaptic plasticity by recruiting post-synaptic receptors into synapses. Recent research investigates the dynamic changes of NPTXs in the cerebrospinal fluid (CSF) as an expression of synaptic damage, possibly related to cognitive impairment. In this review, we summarise the available data on NPTXs structure and expression patterns as well as on their contribution in synaptic function and plasticity and other less well-characterised roles. Moreover, we propose a mechanism for their involvement in synaptic damage and neurodegeneration and assess their potential as CSF biomarkers for neurodegenerative diseases.
Overview
CoChat Summary
TL;DR
This review summarizes neuronal pentraxins (NPTX1, NPTX2, NPTXR) as synaptic organizer proteins and candidate CSF biomarkers of synaptic dysfunction in neurodegeneration. It proposes that NPTX changes may track early synaptic damage and cognitive decline, but current evidence is heterogeneous and mostly limited to CSF.
Key findings
- NPTXs are extracellular scaffolding proteins in the synaptic cleft; NPTX1 and NPTX2 form heteromultimers, bind NPTXR, and cluster/stabilize AMPAR at excitatory synapses onto parvalbumin interneurons. NPTX1 and NPTX2 show opposite activity-dependent regulation: NPTX1 is linked to low activity, apoptosis, and complement-mediated pruning, whereas NPTX2 is activity/BDNF-dependent and promotes plasticity. NPTXR knockout mice had 50% reduced brain NPTX1 and NPTX2 levels.
- In AD CSF, NPTX2 is decreased in MCI and AD versus controls; NPTX2 ratio with tau or p-tau showed the best performance to discriminate AD from controls, and NPTX2 predicted progression and correlated with cognition, medial temporal atrophy, and hippocampal volume. NPTX1 and NPTXR showed a biphasic pattern—elevated in MCI/early stages and decreased in dementia—with NPTXR declining by about 6.9%/year, 6.7%/year, or 10%/year in AD; NPTXR discriminated advanced AD from MCI with AUC = 0.799.
- In genetic and sporadic FTLD, NPTX1, NPTX2, and NPTXR were decreased in symptomatic mutation carriers versus pre-symptomatic carriers/non-carriers; NPTX2 had AUC = 0.71, comparable to neurogranin, and declined over time in symptomatic and pre-symptomatic carriers over age 50. In DLB, CSF NPTX2 was lower than in controls and correlated with visuospatial cognition; NPTX2 was highly upregulated in PD substantia nigra and accumulated in Lewy bodies.
- Proposed pathological mechanisms include astrocyte dysfunction and reduced BDNF lowering NPTX1/NPTX2 release, low neuronal activity driving NPTX1 mitochondrial BAX-dependent apoptosis, impaired TACE/NPTXR cleavage contributing to excitotoxicity, and intensified complement-microglia synaptic pruning.
Methods
- Narrative review of published literature on NPTX structure, expression patterns, physiological synaptic roles, and proposed involvement in synaptic damage and neurodegeneration.
- Summarizes CSF biomarker studies in AD and FTLD in Table 2, plus studies in synucleinopathies, psychiatric disorders, epilepsy, stroke, neuroinflammatory diseases, and brain tumors; cited measurement methods include mass spectrometry, ELISA, Western blot, and antibody suspension bead array.
- No primary cohort or meta-analysis is reported; the paper synthesizes existing studies and proposes mechanistic models.
Limitations
- Stated: reliable NPTX measurements can currently only be performed in CSF due to insufficient assay sensitivity in blood; lumbar puncture is invasive, so longitudinal studies are missing; lack of consistency between studies may result from different inclusion/exclusion criteria and absence of standardized analytical methods; prospective studies are required.
- Stated: observed NPTX alterations reflect a general pathological pattern rather than a disease-specific mechanism, and their suitability for clinical diagnostic purposes requires further investigation.
- Evident: this is a narrative rather than systematic review, and many cited studies are small, cross-sectional, and use heterogeneous assays, which the authors note may explain contradictory NPTX1/NPTXR findings.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
34 Valid · 1 Not valid · 129 Not checked · 26 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Finally, CSF levels of the different NPTXs strongly correlated with each other in both AD and genetic FTLD, indicating an overall reduction of these proteins in CSF (Nilsson et al. 2021; van der Ende et al. 2020; Xiao et al. 2017).”
§ Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration > Neuronal pentraxins in synaptic dysfunction and neurodegeneration: a proposed mechanism > Neuronal pentraxins in neurodegenerative, psychiatric and other disorders of the CNS
What the sources say
- Disputedcites Nilsson et al. 2021 sourceExperimental — accuracy not yet measured
In Results > Clinical cohort (page unavailable), the paper says the pentraxins were exceptions to the generally strong correlations among panel proteins in AD samples. The Discussion (page unavailable) reports only a small decrease in AD for some pentraxins and none for neuronal pentraxin-1. This paper does not report a genetic FTLD cohort. (LLM, conf=0.86)
Checked by a reasoning model — may be wrong.
- Supportedcites van der Ende et al. 2020 source
The Discussion reports that CSF NPTX1 and NPTXR correlated strongly with NPTX2 in genetic FTD and that these findings indicate an overall reduction in NPTXs. This source supports the genetic FTLD part of the multiply cited sentence; its Discussion mentions AD findings but does not report correlations among NPTXs in AD. (LLM, conf=0.90)
- Partly supportedcites Xiao et al. 2017 sourceExperimental — accuracy not yet measured
In Results, ‘CSF NPTX2 provides a biomarker of brain NPTX2’ (Figure 5; page not provided), the paper says CSF NPTX1 and NPTXR strongly correlate with NPTX2 in individual samples and that all three are reduced in AD CSF. It does not report findings for genetic FTLD, so it supports the AD portion but not the claim as applied to both conditions. (LLM, conf=0.90)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“NPTXs might be a selective marker for the imbalance of pyramidal neuron-interneuron microcircuits, thought to underlie cognitive impairment in AD (Xiao et al. 2017).”
§ Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration > Introduction
What the sources say
- Supportedcites Xiao et al. 2017 source
The Results section (‘CSF NPTX2 provides a biomarker of brain NPTX2’; page unavailable) reports reduced CSF levels of NPTX1, NPTX2, and NPTXR in AD and infers that the PV-interneuron circuit is their major CSF source. The Discussion (page unavailable) proposes that NPTX2 down-regulation contributes to pyramidal neuron–PV interneuron circuit dysfunction and cognitive failure in AD. The citing sentence appropriately hedges this as a possible marker and proposed mechanism. (LLM, conf=0.90)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“NPTXs play a role in synaptogenesis (Farhy-Tselnicker et al. 2017; Figueiro-Silva et al. 2015; Sia et al. 2007)”
§ Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration > Neuronal pentraxins: a subfamily of highly conserved pentraxins > Role of neuronal pentraxins in synaptic function and plasticity
What the sources say
- Supportedcites Farhy-Tselnicker et al. 2017 source
The Results section, “Interaction between NP1 and GluA1 Is Necessary for Glypican 4 to Induce Synapse Formation” (page not provided), reports that knocking down neuronal pentraxin 1 (NP1) prevented Gpc4-induced synapse formation. The Introduction (page not provided) also states that removing neuronal pentraxins delays active synapse formation in developing neurons. (LLM, conf=0.94)
- Supportedcites Figueiro-Silva et al. 2015 source
The Discussion states that NP1 limits excitatory synaptogenesis and restricts synapse formation. This directly supports the claim that neuronal pentraxins play a role in synaptogenesis. (LLM, conf=0.94)
- Not checked yetcites Sia et al. 2007 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“BNDF-induced NPTX2 is required for glutamatergic synaptic transmission and LTP in mossy fibres in the dendate gyrus (Mariga et al. 2015; Wibrand et al. 2006).”
§ Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration > Neuronal pentraxins: a subfamily of highly conserved pentraxins > Role of neuronal pentraxins in synaptic function and plasticity
What the sources say
- Partly supportedcites Mariga et al. 2015 sourceExperimental — accuracy not yet measured
The Results section (‘Narp is important for BDNF-dependent synaptic function’; page unavailable) reports impaired mossy-fiber LTP in Narp-deficient mice and finds that BDNF-mediated enhancement of glutamate release depends on Narp. It does not establish that Narp is required for glutamatergic transmission generally, rather than its enhancement by BDNF. The experiments concern the mossy fiber–CA3 pathway, not synapses within the dentate gyrus. (LLM, conf=0.85)
- Not checked yetcites Wibrand et al. 2006 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Under physiological conditions, NPTX2 is mainly secreted from the pre-synaptic terminal into the synapses (Chang et al. 2010; Reti et al. 2002).”
§ Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration > Neuronal pentraxins: a subfamily of highly conserved pentraxins > Role of neuronal pentraxins in synaptic function and plasticity
What the sources say
- Partly supportedcites Chang et al. 2010 sourceExperimental — accuracy not yet measured
The Introduction identifies Narp as neuronal pentraxin 2 (NPTX2) and says it is secreted from presynaptic excitatory neurons and accumulates at synapses on parvalbumin-expressing interneurons. The Results section, “Narp at PV-IN synapses derives from presynaptic neurons,” says it originates primarily from presynaptic neurons. The paper does not establish that NPTX2 is mainly secreted from presynaptic terminals into synapses generally under physiological conditions. (LLM, conf=0.86)
- Not checked yetcites Reti et al. 2002 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
116 more claims · 24 with their cited sources checked
Create a free account to see all 190 claims and to verify the 200 references still open.
- It may state two separate claims as one. 56
- Probably not a substantial claim. 22
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The downregulation of NPTX2 in both genetic and sporadic bvFTD may thus reflect a shared pathophysiology within the FTD disease heterogeneity and suggest that NPTX2 may play a crucial role in the pathogenesis of FTD by contributing to synaptic dysfunction [42].”
From The use of synaptic biomarkers in cerebrospinal fluid to differentiate behavioral variant of frontotemporal dementia from primary psychiatric disorders and Alzheimer’s disease (2024) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The downregulation of NPTX2 in both genetic and sporadic bvFTD may thus reflect a shared pathophysiology within the FTD disease heterogeneity and suggest that NPTX2 may play a crucial role in the pathogenesis of FTD by contributing to synaptic dysfunction [42].”
From The use of synaptic biomarkers in cerebrospinal fluid to differentiate behavioral variant of frontotemporal dementia from primary psychiatric disorders and Alzheimer’s disease (2024) · cites this paper as [42]
Experimental — accuracy not yet measuredIn the citing paper
“NPTX2 is involved in the formation and stabilization of synapses, facilitating proper communication between neurons in the brain, and plays a crucial role in synaptic function and plasticity [42].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration > Introduction
“Given that lumbar puncture is an invasive procedure, longitudinal studies are missing.”
§ Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration > Neuronal pentraxins in synaptic dysfunction and neurodegeneration: a proposed mechanism > Neuronal pentraxins in neurodegenerative, psychiatric and other disorders of the CNS
“A preliminary longitudinal analysis of 13 patients revealed a decline over time in NPTX2 in symptomatic mutation carriers and in pre-symptomatic mutations carriers over the age of 50 years (van der Ende et al. 2020).”
Citations
Cites
1 retracted
RETRACTED: NPTX1 Regulates Neural Lineage Specification from Human Pluripotent Stem Cells
Boles, N. C., Hirsch, S. E., Le, S., Corneo, B., Najm, F., Minotti, A. P., Wang, Q., Lotz, S., Tesar, P. J., & Fasano, C. A. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.01.026 · Cited by 64
RetractedHighly accurate protein structure prediction with AlphaFold
Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03819-2 · Cited by 43,764
Tissue-based map of the human proteome
Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015) · Science · doi:10.1126/science.1260419 · Cited by 15,286
SWISS-MODEL: homology modelling of protein structures and complexes
Waterhouse, A., Bertoni, M., Bienert, S., Studer, G., Tauriello, G., Gumienny, R., Heer, F. T., de Beer, T. A. P., Rempfer, C., Bordoli, L., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky427 · Cited by 13,067
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
UniProt: the universal protein knowledgebase in 2021
The UniProt Consortium, Bateman, A., Martin, M.-J., Orchard, S., Magrane, M., Agivetova, R., Ahmad, S., Alpi, E., Bowler-Barnett, E. H., Britto, R., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa1100 · Cited by 6,372 · cited 1×
“2013; Tseng and Bixby 2011).”
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Improved protein structure prediction using potentials from deep learning
Senior, A. W., Evans, R., Jumper, J., Kirkpatrick, J., Sifre, L., Green, T., Qin, C., Žídek, A., Nelson, A. W. R., Bridgland, A., et al. (2020) · Nature · doi:10.1038/s41586-019-1923-7 · Cited by 3,378
Cited by
Items 101–115 of 115
Kaya, S., Kocabaş, R., Sağlıyan, B., Bayırlı, Ö., Yorulmaz, A. E., & Kandeğer, A. (2026) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-025-02190-x
Backbone resonance assignment of the pentraxin domain of the neuronal pentraxin receptor (NPTXR)
Pozhidaeva, A., Li, Y., Pustovalova, Y. E., Hoch, J. C., Martinelli, D. C., Simon, B., & Hao, B. (2026) · Biomolecular NMR Assignments · doi:10.1007/s12104-025-10259-w
Daimon, E., Shibukawa, Y., Yamazaki, N., Kawai, M., Kinoshita, S., & Okamoto, N. (2026) · Brain and Development · doi:10.1016/j.braindev.2026.104503
Guise, A. J., Ferber, K. L., Young, D., Edwards, A., Sabouri, S., Fraser, K. B., Milliman, E. J., Plowey, E. D., Zoghbi, J., Fradette, S., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102648
Wang, H., Bundo, M., Nakachi, Y., Kanai, A., Yamamoto, Y., Miyazaki, H., Toyoshima, F., Shima, Y., Sakai, M., Yu, Z., et al. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03629-w · Cited by 1
Mao, F., Yang, Y., Jiang, Z., Le, Q., & Jin, T. (2026) · Neuroreport · doi:10.1097/wnr.0000000000002272
Paitel, E. R., Pettigrew, C. A., Moghekar, A., Miller, M. I., Faria, A. V., Albert, M., Na, C. H., Worley, P. F., & Soldan, A. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1851829
Synaptic dysfunction as a major driver in Alzheimer's disease: Beyond the amyloid paradigm
Mierzwa, N., & Wężyk, M. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106858
Klepacki, H., Ordak, M., Kowalczuk, K., Hermanowicz, J. M., & Waszkiewicz, N. (2026) · Antioxidants · doi:10.3390/antiox15070908
Lyndin, M., Janicot, M., Justus, M., Schiemann, P., & Wennemuth, G. (2026) · Cancer Cell International · doi:10.1186/s12935-026-04438-5
Alzheimer’s disease blood biomarkers reveal proteomic modules of disease progressionPreprint
Butler, R. R., Brown, M. P., Weber, A., Cary, G. A., Guen, Y. L., Losada, P. M., Mendiola, J. H., Henderson, V. W., Sha, S. J., Poston, K. L., et al. (2026) · medRxiv · doi:10.64898/2026.08.14.26360394 · Cited by 1
Tang, N., Xia, F., Freasier, H., Tien, P. C., Glesby, M. J., Merenstein, D., French, A. L., McKay, H., Diaz, M. M., Ofotokun, I., et al. (2026) · Cells · doi:10.3390/cells15171581
Бунеева, О. А., Капица, И. Г., Zavialova, M. G., Kaloshina, S. A., Zgoda, V. G., & Ae, M. (2026) · Biomeditsinskaya Khimiya · doi:10.18097/pbmcr1718
Li, J., Garg, V., Martiartu, A., Tanzillo, A. F., Zhang, Y., & Petros, T. J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.08.749487
Spillman, A. M., Alsop, E. B., Gittings, L. M., Garcia‐Mansfield, K., Piras, I. S., Bonfitto, A., Martinez, M. N., Sharma, R., Preller, K. R., Huentelman, M. J., et al. (2026) · Acta Neuropathologica · doi:10.1007/s00401-026-03084-5
Metadata
- Authors
- Gómez de San José, N., Massa, F., Halbgebauer, S., Oeckl, P., Steinacker, P., & Otto, M.
- Affiliations
- Universität Ulm (DE)
- Corresponding author
- Otto, Markus
- ORCID
- Venue
- Journal of Neural Transmission
- Published
- 2021-08-30
- Volume
- 129
- Issue
- 2
- Pages
- 207-230
- ISSN
- 0300-9564 (ISSN-L)
- 1435-1463
- PMC
- PMC8866268
- OpenAlex
- W3197743626
- Cited by
- 112
- References
- 181
- Citations by year
- 2026: 24 · 2025: 36 · 2024: 31 · 2023: 12 · 2022: 9
- FWCI
- 1.33
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Journal of Neural Transmission (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by)
- OPen Access Repositorium der Universität Ulm (OPARU) (Ulm University) (submittedVersion, other-oa)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- Universität Ulm, Kommunikations- und Informationszentrum (kiz) (cc-by)
- Funders
- h2020 marie skłodowska-curie actions (860197)
- Universität Ulm
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Biomarkers in Disease Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- synaptic dysfunction, neurodegeneration, cerebrospinal fluid biomarkers, synaptic plasticity, cognitive impairment, neurodegenerative disease diagnosis
- MeSH terms
- Pentraxins, C-Reactive Protein, Nerve Tissue Proteins, Neuronal Plasticity, Synapses, Biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.